Laura Deming (born 1994) is a venture capitalist whose work focuses on life extension, and using biological research to reduce or reverse the effects of aging.

[7][10] The Longevity Fund investments include Unity Biotechnology, which develops senolytic drugs targeting diseases of aging, Navitor Pharmaceuticals, and Metacrine.

[11] The program graduated its first cohort of six on October 10, 2018, including Fauna Bio, a startup using the biology of hibernation to aid in heart attack and stroke recovery.

[12][13] In August 2018, Deming also began advising the newly launched Pioneer, a fund designed to find talent and "lost Einsteins" around the world, for projects in longevity.

[17] Colville, the fund's co-founder, has been recognized for his leadership in driving innovation and advocating for regulatory reforms in aging-related drug development.